Porton Down, UK, 19 October 2006: GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) and Bayer HealthCare, Pharmaceuticals Division - Canada (“Bayer”) announce that GW has submitted a regulator... more
Porton Down, UK, 3 October 2006 – GW Pharmaceuticals plc (AIM: GWP) announces today that results from two Phase III studies of Sativex ® were presented at Europe's leading multiple sclerosis (MS) conf... more
Porton Down, UK, 5 September 2006 - GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) today announces that it has filed a regulatory submission in selected European countries for Sativex®, its... more
Porton Down, UK, 9 August 2006 - GW Pharmaceuticals plc (AIM: GWP) announces the start of a second pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pai... more
Porton Down, UK, 20 June 2006: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new medicines based on cannabis and other controlled drugs, announces its interim results... more
GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its interim results for the six months... more
GW Pharmaceuticals plc (AIM: GWP) is today pleased to announce the appointment of Investec Bank (UK) Limited as Nominated Adviser and Broker to the Company with immediate effect.... more
Porton Down, UK, 17 March 2006 - GW Pharmaceuticals plc (AIM: GWP) today announces preliminary results from a Phase III study of Sativex® in the relief of spasticity in people with Multiple Sclerosis ... more
GW Pharmaceuticals today announces the appointment of Mr David Morrison as a non-executive director with immediate effect. Mr Morrison replaces Mr Peter Mountford, who today resigns as a non-executive... more
GW Pharmaceuticals plc, the company which develops and manufactures a range of new medicines based on cannabis and other controlled drugs, announces its preliminary results for the year ended 30 Septe... more
GW Pharmaceuticals (AiM:GWP) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for Sativex®, a cannabis-derived, oro-mucosal ... more
GW Pharmaceuticals plc (AiM:GWP) today announces that it has signed an agreement with a United States-based institutional investor to raise $15 million (£8.6 million) before expenses through a placing... more
